In short
Clinical trials are studying Apg777 in people with moderate-to-severe atopic dermatitis, also called eczema. These studies aim to check long-term safety, tolerability, and how well Apg777 works compared with placebo. Both trials are Phase 2 and are enrolling adults with this skin condition.
Key points
- Two Phase 2 clinical trials are studying Apg777 in people with moderate-to-severe atopic dermatitis, also called eczema. One trial focuses on long-term safety and effectiveness, with follow-up for up to 3 years. The other trial compares Apg777 with placebo after 16 weeks and looks at skin improvement using EASI results. Both studies are authorised and are testing Apg777 in patients with the same skin condition.
Trial overview
Clinical trials of Apg777 are being done in people with atopic dermatitis, which is also called eczema. Both studies are Phase 2 and are currently authorised.
The two trials are looking at whether Apg777 can help people with moderate-to-severe disease and whether it can be used safely over time.
Who is being studied
Both studies focus on patients with moderate-to-severe atopic dermatitis, meaning eczema that is more serious and can affect daily life more strongly.
The trial data do not list full eligibility rules, but the target population is clearly adults or patients with this skin condition who meet the study criteria.
Study designs and phases
Both studies are interventional, which means the researchers give a study treatment and then measure what happens.
One study is designed to evaluate the long-term safety and effectiveness of Apg777, with follow-up for up to 3 years.
The other study compares Apg777 with placebo, which is a look-alike treatment with no active study drug, to see whether Apg777 works better than no active treatment.
Outcomes being measured
The long-term study measures the number of participants with treatment-emergent adverse events, meaning health problems that start after treatment begins, over a period of up to 3 years.
The other study measures change in Eczema Area and Severity Index (EASI) from baseline to Week 16 in Part A. Baseline means the starting point before treatment begins.
In Part B, the same study measures the proportion of patients who achieve EASI 75 at Week 16, which means a 75% or greater improvement in the EASI score from the start of the trial.
Key trial details
Trial 2024-519795-11-00 includes 446 participants and focuses on long-term safety and effectiveness in atopic dermatitis.
Trial NCT06395948 includes 431 participants and has two parts: one looks at overall change in EASI after 16 weeks, and the other compares different doses of Apg777 with placebo after 16 weeks.
Both studies are important because they help show whether Apg777 may be useful for patients with moderate-to-severe eczema and how its effects compare with placebo.